This is the first clinical trial of S1B-408 in women with sexual dysfunction. A prior 4-week trial in premenopausal women with Hypoactive Sexual Desire Disorder showed that orgasmic function improved with Lorexys (TM). This pilot trial tests for improvement in orgasmic function, safety, and tolerability of a different but related test article.
S1B-408 is a proprietary combination of agents proven safe and effective in other CNS indications. The combination drug is aimed at treating women's sexual dysfunction disorders. Its two components each have pro-sexual effects. However, the efficacy of each when given alone has been limited. Moreover, each component has side effects which, while benign, may limit the drug's utility: activation (agitation, anxiety, insomnia) with one; sedation (somnolence, fatigue, etc) with the other. The goal of this trial is to show that, when formulated in the proper (fixed) ratio, the combination of these two drugs strengthens their pro-sexual effects for orgasmic dysfunction while mitigating the opposing side effect profiles. For this pilot study, the goal for exposure is to seek rapid onset of action with minimal dosing.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
30
Medication with multiple monoamine activities
Female Sexual Function Index (FSFI): orgasm domain
sum of 3 items on orgasmic frequency, difficulty, and satisfaction, each rated 0 or 1 (worst) to 5 (best)
Time frame: 7 or 28 day recall
Changes in Sexual Function Questionnaire (CSFQ): orgasm
sum of 3 items on orgasmic frequency, pleasure, and ability, each rated 1 (worst) to 5 (best)
Time frame: 7 day recall
CSFQ total score
sum of 14 items on all aspects of female sexual response, scored from 14 to 70 (best)
Time frame: "now" or 7 day recall
FSFI total score
sum of 19 items on 6 aspects of female sexual response, scored from 4 (worst) to 95 (best)
Time frame: Prior 7 or 28 days
Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) items 13, 14, and 15 scores
3 items on sexual distress re desire, arousal, and orgasm, each scored from 0 to 4 (best)
Time frame: Prior 7 or 28 days
Sexual Activity Log (SAL), orgasms
Sexual Activity Log count of orgasms
Time frame: 1-7 day recall
SAL proportion of sexual activities with orgasm
Sexual Activity Log count of orgasms over times engaged in sex; best would be 1.0
Time frame: 1-7 day recall
Sexual Activity Log (SAL) satisfying sexual events
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Count of sexual events that were satisfying
Time frame: 1-7 day recall
Patient's Global Impression of Change
single question rated from 1 (best) to 7 (worst) asking improvement vs none or worsening
Time frame: 4 weeks